-
1.发明公开
公开(公告)号：KR1020100088749A
公开(公告)日：2010-08-11
申请号：KR1020090007836
申请日：2009-02-02
Applicant: 서울대학교산학협력단
IPC: A61K36/254 , A61P17/00 , A23L1/30 , A61K31/70
CPC classification number: A61K36/254 , A23L2/52 , A23L29/035 , A23V2200/318 , A61K9/00 , A61K31/7048 , A61K2236/17 , A61K2236/30 , Y10S514/828
Abstract: PURPOSE: A pharmaceutical composition containing cyanidin-3-O-(2''-xylosyl) glucoside is provided to suppress COX-2 and the transcription factors such as AP-1 and NF-kappaB. CONSTITUTION: A pharmaceutical composition for preventing and treating dermatitis contains 0.1-50 weight% of Acanthopanax sessiliforium extract as an active ingredient. The Acanthopanax sessiliforium extract is obtained by drying Acanthopanax sessiliforium at 30-40°C for 44-52 hours, pulverizing, adding 50-99% of ethanol to the dried powder and extracting for 20-28 hours. The concentration of Acanthopanax sessiliforium is 10uM-1mM. The dermatitis includes skin cancer or skin inflammation.
Abstract translation: 目的：提供含有花青素-3-O-（2“ - 木糖基）葡萄糖苷的药物组合物，以抑制COX-2和转录因子如AP-1和NF-κB。 构成：用于预防和治疗皮炎的药物组合物含有0.1-50重量％的刺五加提取物作为活性成分。 刺五加提取物通过在30-40℃下干燥刺五加44-52小时，粉碎，向干粉中加入50-99％的乙醇并提取20-28小时得到。 刺五加浓度为10uM-1mM。 皮炎包括皮肤癌或皮肤炎症。
-
公开(公告)号：KR101293274B1
公开(公告)日：2013-08-02
申请号：KR1020110012561
申请日：2011-02-11
Applicant: 서울대학교산학협력단
IPC: A61K31/352 , A61K31/35 , A61P17/00
Abstract: 본 발명은 데하이드로글리아스페린 디(dehydroglyasperin D; DHGA-D)를 유효성분으로 포함하는 것을 특징으로 하는 피부질환 예방 또는 치료용 조성물에 관한 것으로, DHGA-D가 MMP-1과 직접 결합하여, MMP-1의 활성을 감소시키고, S-UV 조사에 의해 증가한 MMP-1의 발현을 억제함이 확인되었다. 또한, S-UV의 조사에 의해 증가한 COX-2의 발현과 p38과 JNK의 인산화를 감소시키는 효과도 확인되었다. 따라서, 본 발명의 DHGA-D는 피부질환 예방 또는 치료용 조성물로 개발되어 사용될 수 있다.
-
公开(公告)号：KR1020120092474A
公开(公告)日：2012-08-21
申请号：KR1020110012561
申请日：2011-02-11
Applicant: 서울대학교산학협력단
IPC: A61K31/352 , A61K31/35 , A61P17/00
Abstract: PURPOSE: A composition containing dehydroglyasperin D(DHGA-D) for preventing or treating cutaneous disorders is provided to suppress MMP-1 expression and reduce p38 and JNK phosphorylation. CONSTITUTION: A composition for preventing or treating cutaneous disorders contains 10uM-1mM of dehydroglyasperin D(DHGA-D) as an active ingredient. The cutaneous disorders include skin aging, dermatitis, or skin cancer. The composition is a pharmaceutical composition. The formulation of the pharmaceutical composition includes plasters, granules, lotions, liniments, lemonades, aromatic waters, powders, syrups, ophthalmic ointments, liquids and solutions, aerosols, extracts, elixirs, ointments, fluid extracts, emulsions, suspensions, decoctions, infusions, pills, or soft or hard gelatin capsules.
Abstract translation: 目的：提供含有用于预防或治疗皮肤病症的脱氢甘油D（DHGA-D）的组合物，以抑制MMP-1的表达并降低p38和JNK磷酸化。 构成：用于预防或治疗皮肤疾病的组合物含有10uM-1mM的脱氢甘油D（DHGA-D）作为活性成分。 皮肤疾病包括皮肤老化，皮炎或皮肤癌。 组合物是药物组合物。 药物组合物的制剂包括膏药，颗粒剂，洗剂，搽剂，柠檬水，芳香水，粉剂，糖浆剂，眼用软膏，液体和溶液，气溶胶，提取物，酏剂，软膏，液体提取物，乳液，悬浮液， 丸或软或硬明胶胶囊。
-
公开(公告)号：KR1020140054536A
公开(公告)日：2014-05-09
申请号：KR1020120120124
申请日：2012-10-29
Applicant: 서울대학교산학협력단
IPC: A61K31/352 , A61K31/35 , A61K31/351 , A61P17/00
Abstract: The present invention relates to a pharmaceutical composition comprising quercetagetin as an active ingredient for preventing and treating skin diseases or a food composition for alleviating skin diseases. Since the composition comprises quercetagetin, as an active ingredient, which inhibits phosphorylation of JNK and PI3K signaling proteins by combining with JNK-1 and PI3K which are important signaling proteins for regulating inflammatory responses and shows an effect of suppressing the activity of AP-1 and NF-κB which are indicators of inflammation, the composition has an excellent effect for preventing or treating skin diseases such as skin inflammation and skin cancer.
Abstract translation: 本发明涉及包含槲皮素作为预防和治疗皮肤病的活性成分的药物组合物或用于缓解皮肤病的食品组合物。 由于组合物包含槲皮素作为活性成分，其通过与作为调节炎症反应的重要信号蛋白的JNK-1和PI3K结合来抑制JNK和PI3K信号蛋白的磷酸化，并且显示出抑制AP-1的活性和 作为炎症指标的NF-κB，该组合物对预防或治疗皮肤疾病如皮肤炎症和皮肤癌具有优异的效果。
-
-
-
Search Results
4
records
(took 0.018 seconds)
